Oral Contraceptives as Infertility Treatments for Premature Ovarian Failure

Navy General Hospital, Beijing

Status: Unknown

Conditions: Menopause, Premature; Primary Ovarian Insufficiency

Treatments: Drug: Drospirenone and ethinyl estradiol combination (Yasmin)

Study type: Interventional

Funder types: Other

Identifiers

NCT02757469

OCPOF-1

Details and patient eligibility

About

Premature ovarian insufficiency (POI) is a life-changing condition that affects women in their reproductive age. There is a lack of reports which focus on how to improve the reproductive outcome of these women who wish to conceive spontaneously or use assisted conception with their own oocytes. However, one could surmise that it is important to lower gonadotropin levels into the physiological range before embarking on any treatment, even if natural conception is the only choice for the woman/couple.

Enrollment: 20 estimated patients

Sex: Female

Ages: 18 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• premature ovarian failure
• normal anatomy
• normal secondary sexual characteristics
• essential or idiopathic

Exclusion criteria

• chromosomal disorder
• iatrogenic injury
• autoimmune diseases
• infection
• genetic diseases

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

Yasmin

Experimental group

Description:

Pregnancies will occur while the women are taking oral contraceptives (Yasmin). The possible role of exogenous estrogens in sensitizing the granulosa cells to the effect of follicle-stimulating hormone and thereby inducing ovulation and conception in some women with premature ovarian failure is examined.

Treatment:

Drug: Drospirenone and ethinyl estradiol combination (Yasmin)